Calretinin, thrombomodulin, CEA, and CD15: A useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma

Human Pathology

Volumn 32, Issue 5, 2001, Pages 529-536

  Comin, Camilla E ^a   Novelli, Luca ^a   Boddi, Vieri ^a   Paglierani, Milena ^a   Dini, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adenocarcinoma; Calretinin; CD 44H; HBME 1; Immunohistochemistry; Mesothelioma; Thrombomodulin

Indexed keywords

CALRETININ; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; THROMBOMODULIN;

ARTICLE; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; PLEURA; PLEURA MESOTHELIOMA; SENSITIVITY AND SPECIFICITY; STAINING;

EID: 0034994145     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2001.24329     Document Type: Article

References (41)

1. Mucin positive epithelial mesotheliomas: A histochemical, immunohistochemical, and ultrastructural comparison with pulmonary mucin producing pulmonary adenocarcinoma
2. The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma
3. The pathology of malignant mesothelioma, including immunohistology and ultrastructure
4. Malignant mesothelioma of the pleura: Current surgical pathology
5. The immunohistochemical diagnosis of epithelial mesothelioma
6. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced epitope retrieval
7. Calretinin: A novel immunocytochemical marker for mesothelioma
8. Calretinin: A novel tool for diagnostic immunohistochemistry
9. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type
10. Calretinin: A selective marker of normal and neoplastic mesothelial cells in serous effusions
11. E-cadherin and calretinin: A useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma
12. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma
13. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura
14. Thrombomodulin expression can be used to differentiate between mesotheliomas and adenocarcinomas
15. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma
16. The diagnostic value of thrombomodulin immunolocalization in serous effusions
17. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura
18. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma
19. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma
20. Mesothelioma-binding antibodies: Thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma
21. CD44 is the principal cell surface receptor for hyaluronate
22. CD44 and its interactions with extracellular matrix
23. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family
24. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma
25. Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas, and reactive mesothelial hyperplasias
26. Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: Disappointing results in cytology material
27. Immunopathologic and molecular studies as an aid to the diagnosis to malignant mesothelioma
28. Ultrastructural and immunohistochemical features of common lung tumors: An overview
29. Malignant pleural mesothelioma: Some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985
30. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical, ultrastructural, and immunohistologic study of 103 cases
31. Anti-cytokeratin 5/6: A positive marker for epithelioid mesothelioma
32. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas
33. Absence of carcinoembryonic antigen-like material in mesothelioma. An immunohistochemical differentiation from other lung cancers
34. Ber-EP4: New monoclonal antibody which distinguishes epithelia from mesothelia
35. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma
36. The application of a monoclonal antibody to the differentiation of benign and malignant mesothelial proliferations from adenocarcinomas
37. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3)
38. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma
39. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours
40. Antigenic phenotype of malignant mesothelioma and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu-M1 antigen
41. The pleura